TD Asset Management Inc. boosted its stake in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 2.1% in the second quarter, Holdings Channel reports. The firm owned 355,698 shares of the biopharmaceutical company’s stock after acquiring an additional 7,198 shares during the period. TD Asset Management Inc.’s holdings in Alexion Pharmaceuticals were worth $46,589,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors also recently made changes to their positions in ALXN. Dimensional Fund Advisors LP boosted its position in Alexion Pharmaceuticals by 17.8% during the fourth quarter. Dimensional Fund Advisors LP now owns 635,679 shares of the biopharmaceutical company’s stock worth $61,893,000 after purchasing an additional 95,895 shares during the period. Geode Capital Management LLC raised its stake in shares of Alexion Pharmaceuticals by 7.5% in the fourth quarter. Geode Capital Management LLC now owns 2,681,909 shares of the biopharmaceutical company’s stock valued at $260,616,000 after purchasing an additional 187,834 shares in the last quarter. Louisiana State Employees Retirement System raised its stake in Alexion Pharmaceuticals by 0.9% during the first quarter. Louisiana State Employees Retirement System now owns 11,800 shares of the biopharmaceutical company’s stock worth $1,595,000 after acquiring an additional 100 shares in the last quarter. Retirement Systems of Alabama raised its stake in Alexion Pharmaceuticals by 1.2% during the first quarter. Retirement Systems of Alabama now owns 104,056 shares of the biopharmaceutical company’s stock worth $14,066,000 after acquiring an additional 1,282 shares in the last quarter. Finally, Prime Capital Investment Advisors LLC acquired a new position in Alexion Pharmaceuticals during the first quarter worth $74,000. 93.77% of the stock is owned by hedge funds and other institutional investors.
Shares of NASDAQ ALXN traded up $1.55 during mid-day trading on Thursday, reaching $109.20. 21,404 shares of the company’s stock were exchanged, compared to its average volume of 2,246,375. The stock has a market capitalization of $24.37 billion, a price-to-earnings ratio of 15.41, a price-to-earnings-growth ratio of 1.03 and a beta of 1.65. The company has a debt-to-equity ratio of 0.26, a current ratio of 4.04 and a quick ratio of 3.56. The firm’s fifty day moving average is $119.99. Alexion Pharmaceuticals, Inc. has a twelve month low of $92.56 and a twelve month high of $141.86.
Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its earnings results on Wednesday, July 24th. The biopharmaceutical company reported $2.64 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.13 by $0.51. Alexion Pharmaceuticals had a return on equity of 20.23% and a net margin of 29.64%. The business had revenue of $1.20 billion for the quarter, compared to analyst estimates of $1.18 billion. During the same quarter last year, the firm earned $2.07 EPS. Alexion Pharmaceuticals’s revenue for the quarter was up 15.1% compared to the same quarter last year. As a group, research analysts predict that Alexion Pharmaceuticals, Inc. will post 9 EPS for the current year.
Several research analysts have issued reports on the company. ValuEngine lowered Alexion Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Thursday, August 8th. Citigroup dropped their price objective on Alexion Pharmaceuticals from $180.00 to $165.00 and set a “buy” rating for the company in a research note on Thursday, May 23rd. TheStreet upgraded Alexion Pharmaceuticals from a “c” rating to a “b” rating in a research note on Thursday, April 25th. Raymond James increased their price objective on Alexion Pharmaceuticals from $164.00 to $168.00 and gave the stock an “outperform” rating in a research note on Thursday, July 25th. Finally, BidaskClub lowered Alexion Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, July 31st. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and twelve have assigned a buy rating to the company. Alexion Pharmaceuticals has a consensus rating of “Buy” and an average target price of $162.88.
In other Alexion Pharmaceuticals news, EVP Indrani Lall Franchini sold 4,500 shares of the firm’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $132.78, for a total value of $597,510.00. Following the completion of the transaction, the executive vice president now directly owns 29,627 shares in the company, valued at $3,933,873.06. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Bros. Advisors Lp Baker sold 300,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 30th. The shares were sold at an average price of $123.74, for a total value of $37,122,000.00. The disclosure for this sale can be found here. In the last three months, insiders sold 428,567 shares of company stock worth $53,420,869. 4.08% of the stock is owned by insiders.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.
Recommended Story: What is Cost of Goods Sold (COGS)?
Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.